company background image
YEWB

Yew Bio-Pharm Group OTCPK:YEWB Stock Report

Last Price

US$0.0001

Market Cap

US$5.2k

7D

0%

1Y

-99.9%

Updated

28 Sep, 2022

Data

Company Financials
YEWB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

YEWB Stock Overview

Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the People’s Republic of China and the United States.

Yew Bio-Pharm Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Yew Bio-Pharm Group
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.29
52 Week LowUS$0.0001
Beta-1.34
1 Month Change-99.33%
3 Month Change-99.91%
1 Year Change-99.93%
3 Year Change-99.88%
5 Year Change-99.96%
Change since IPO-99.99%

Recent News & Updates

Shareholder Returns

YEWBUS FoodUS Market
7D0%-1.9%-2.0%
1Y-99.9%0.3%-20.3%

Return vs Industry: YEWB underperformed the US Food industry which returned 0.1% over the past year.

Return vs Market: YEWB underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is YEWB's price volatile compared to industry and market?
YEWB volatility
YEWB Average Weekly Movementn/a
Food Industry Average Movement5.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: Insufficient data to determine YEWB's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine YEWB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200735Guifang Qihttps://www.yewbiopharm.com

Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the People’s Republic of China and the United States. It offers traditional Chinese medicine (TCM) raw materials in the form of yew tree branches and leaves to manufacture TCM containing taxol. The company is also involved in processing and selling yew raw materials used in the manufacture of traditional Chinese medicine; growing and selling yew tree seedlings and mature trees, including potted miniature yew trees; manufacturing and selling furniture and handicrafts made of yew tree timber; selling agricultural products, such as yew candles, pine needle extracts, taxus cuspidate extracts, northeast yew extracts, and yew essential oil soaps; and selling wood ear mushroom.

Yew Bio-Pharm Group Fundamentals Summary

How do Yew Bio-Pharm Group's earnings and revenue compare to its market cap?
YEWB fundamental statistics
Market CapUS$5.17k
Earnings (TTM)US$402.84k
Revenue (TTM)US$29.05m

0.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YEWB income statement (TTM)
RevenueUS$29.05m
Cost of RevenueUS$28.89m
Gross ProfitUS$162.90k
Other Expenses-US$239.95k
EarningsUS$402.84k

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0078
Gross Margin0.56%
Net Profit Margin1.39%
Debt/Equity Ratio19.3%

How did YEWB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is YEWB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YEWB?

Other financial metrics that can be useful for relative valuation.

YEWB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA2.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does YEWB's PE Ratio compare to its peers?

YEWB PE Ratio vs Peers
The above table shows the PE ratio for YEWB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average6.2x
ECGR Bellatora
0.6xn/aUS$14.1k
MRGO Margo Caribe
7xn/aUS$30.6m
GGRO.U Golden Growers Cooperative
9.5xn/aUS$71.3m
DAAG Data Agro
7.2xn/aPK₨64.8m
YEWB Yew Bio-Pharm Group
0.01xn/aUS$5.2k

Price-To-Earnings vs Peers: YEWB is good value based on its Price-To-Earnings Ratio (0x) compared to the peer average (6.2x).


Price to Earnings Ratio vs Industry

How does YEWB's PE Ratio compare vs other companies in the US Food Industry?

Price-To-Earnings vs Industry: YEWB is good value based on its Price-To-Earnings Ratio (0x) compared to the US Food industry average (18.2x)


Price to Earnings Ratio vs Fair Ratio

What is YEWB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YEWB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.01x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate YEWB's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of YEWB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate YEWB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate YEWB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Yew Bio-Pharm Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.5%

Forecasted Food, Beverage & Tobacco industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yew Bio-Pharm Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Yew Bio-Pharm Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Yew Bio-Pharm Group's filings and announcements here.

Past Performance

How has Yew Bio-Pharm Group performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: YEWB has high quality earnings.

Growing Profit Margin: YEWB became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: YEWB's earnings have declined by 21.9% per year over the past 5 years.

Accelerating Growth: YEWB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: YEWB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Food industry (0.3%).


Return on Equity

High ROE: YEWB's Return on Equity (0.8%) is considered low.


Discover strong past performing companies

Financial Health

How is Yew Bio-Pharm Group's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: YEWB's short term assets ($13.9M) exceed its short term liabilities ($12.5M).

Long Term Liabilities: YEWB's short term assets ($13.9M) exceed its long term liabilities ($2.1M).


Debt to Equity History and Analysis

Debt Level: YEWB's net debt to equity ratio (19.2%) is considered satisfactory.

Reducing Debt: YEWB's debt to equity ratio has increased from 10.2% to 19.3% over the past 5 years.

Debt Coverage: YEWB's debt is well covered by operating cash flow (133.8%).

Interest Coverage: YEWB's interest payments on its debt are not well covered by EBIT (2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Yew Bio-Pharm Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Yew Bio-Pharm Group Dividend Yield vs Market
How does Yew Bio-Pharm Group dividend yield compare to the market?
SegmentDividend Yield
Company (Yew Bio-Pharm Group)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Food)2.7%
Analyst forecast in 3 Years (Yew Bio-Pharm Group)n/a

Notable Dividend: Unable to evaluate YEWB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate YEWB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YEWB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YEWB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as YEWB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.0yrs

Average board tenure


CEO

Guifang Qi (60 yo)

11.75yrs

Tenure

US$69,600

Compensation

Madame. Guifang Qi serves as Secretary of Bio-Pharm Group, Inc since December 15, 2013 and also serves as its Chief Executive Officer, Chief Financial Officer, President and Chairman of the Board since Jul...


CEO Compensation Analysis

Guifang Qi's Compensation vs Yew Bio-Pharm Group Earnings
How has Guifang Qi's remuneration changed compared to Yew Bio-Pharm Group's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2021n/an/a

US$403k

Jun 30 2021n/an/a

US$3m

Mar 31 2021n/an/a

US$4m

Dec 31 2020US$70kUS$70k

US$1m

Sep 30 2020n/an/a

-US$127k

Jun 30 2020n/an/a

US$61k

Mar 31 2020n/an/a

US$760k

Dec 31 2019US$70kUS$70k

US$986k

Sep 30 2019n/an/a

US$293k

Jun 30 2019n/an/a

-US$1m

Mar 31 2019n/an/a

-US$1m

Dec 31 2018US$70kUS$70k

-US$1m

Sep 30 2018n/an/a

-US$6m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

US$3m

Dec 31 2017US$70kUS$70k

US$3m

Sep 30 2017n/an/a

US$10m

Jun 30 2017n/an/a

US$10m

Mar 31 2017n/an/a

US$1m

Dec 31 2016US$70kUS$70k

US$2m

Sep 30 2016n/an/a

US$5m

Jun 30 2016n/an/a

US$5m

Mar 31 2016n/an/a

US$5m

Dec 31 2015US$52kUS$52k

US$5m

Compensation vs Market: Insufficient data to establish whether Guifang's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Guifang's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: YEWB's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of YEWB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders22,743,21244.0%
General Public28,956,78856.0%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 3 shareholders own 43.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
38.88%
Zhiguo Wang
20,103,475$2.0k0%no data
4.72%
Guifang Qi
2,439,737$244.00%no data
0.39%
Xuehai Wu
200,000$20.00%no data

Company Information

Yew Bio-Pharm Group, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Yew Bio-Pharm Group, Inc.
  • Ticker: YEWB
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Agricultural Products
  • Sector: Food, Beverage & Tobacco
  • Implied Market Cap: US$5.170k
  • Shares outstanding: 51.70m
  • Website: https://www.yewbiopharm.com

Number of Employees


Location

  • Yew Bio-Pharm Group, Inc.
  • 9460 Telstar Avenue
  • Suite 6
  • El Monte
  • California
  • 91731
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YEWBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2013

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.